S
VRDN icon

SignatureFD’s Viridian Therapeutics VRDN Stock Holding History

SignatureFD’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349 Sell
19
-49
-72% -$789 ﹤0.01% 3389
2026
Q1 		$1.33K Buy
68
+49
+258% +$1.46K ﹤0.01% 3151
2025
Q4 		$591 Hold
19
– – ﹤0.01% 3206
2025
Q3 		$410 Hold
19
– – ﹤0.01% 3223
2025
Q2 		$266 Sell
19
-987
-98% -$13.4K ﹤0.01% 3166
2025
Q1 		$13.6K Sell
1,006
-88
-8% -$1.5K ﹤0.01% 2244
2024
Q4 		$21K Buy
1,094
+94
+9% +$2.04K ﹤0.01% 2039
2024
Q3 		$22.8K Buy
+1,000
New +$16.3K ﹤0.01% 1978

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SignatureFD's VRDN Position: Q2 2026 in Review

SignatureFD reduced its Viridian Therapeutics (VRDN) stake by 72% in Q2 2026, selling an estimated $789 and leaving 19 shares worth $349. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

SignatureFD first reported a position in VRDN in Q3 2024 and has held it in 8 quarters since. The position peaked at $22.8K in Q3 2024. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • SignatureFD held 19 shares of Viridian Therapeutics worth $349 as of Q2 2026.
  • SignatureFD sold 49 Viridian Therapeutics shares in Q2 2026, an estimated $789.
  • Viridian Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3389 holding.
  • SignatureFD first reported a position in Viridian Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • SignatureFD's Viridian Therapeutics position peaked at $22.8K in Q3 2024.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.